Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: Efficacy, renal function and safety at 1 year

American Journal of Transplantation

Volumn 12, Issue 9, 2012, Pages 2446-2456

  Vincenti, F ^a   Tedesco Silva, H ^b   Busque, S ^c   O'Connell, P ^d   Friedewald, J ^e   Cibrik, D ^f   Budde, K ^g   Yoshida, A ^h   Cohney, S ⁱ   Weimar, W ^j   Kim, Y S ^k   Lawendy, N ^l   Lan, S P ^l   Kudlacz, E ^l   Krishnaswami, S ^l   Chan, G ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^c STANFORD UNIVERSITY   (United States)

^d WESTMEAD HOSPITAL   (Australia)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h HENRY FORD HOSPITAL   (United States)

ⁱ ROYAL MELBOURNE HOSPITAL   (Australia)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k Seoul National University College of Medicine   (South Korea)

^l PFIZER INC   (United States)

more..

Author keywords

cyclosporine; kidney; renal function; tofacitinib

Indexed keywords

ANTIHYPERTENSIVE AGENT; BASILIXIMAB; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TOFACITINIB;

ADULT; ANEMIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INFECTION; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADULT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JANUS KINASE 3; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES;

EID: 84865587510     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04127.x     Document Type: Article

References (24)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B,. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383. (Pubitemid 38282293)
2. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333. (Pubitemid 37509740)
3. Flechner SM,. Sirolimus in kidney transplantation indications and practical guidelines: De novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 2009; 87: S1-S6.
4. Srinivas TR, Schold JD, Guerra G, Eagan A, Bucci CM, Meier-Kriesche HU,. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007; 7: 586-594. (Pubitemid 46376441)
5. Vincenti F, Ramos E, Brattstrom C, et al,. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282-1287. (Pubitemid 32507148)
6. Weir MR, Diekmann F, Flechner SM, et al,. mTOR inhibition: The learning curve in kidney transplantation. Transpl Int 2010; 23: 447-460.
7. Busque S, Leventhal J, Brennan DC, et al,. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: A pilot study in de novo kidney allograft recipients. Am J Transplant 2009; 9: 1936-1945.
8. Racusen LC, Colvin RB, Solez K, et al,. Antibody-mediated rejection criteria-An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714. (Pubitemid 36745243)
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470. (Pubitemid 29135798)
10. Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR,. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683-1689.
11. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575. (Pubitemid 350294223)
12. Silva HT, Jr,., Yang HC, Abouljoud M, et al,. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595-608. (Pubitemid 46376444)
13. Gill JS, Tonelli M, Mix CH, Pereira BJ,. The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol 2003; 14: 1636-1642. (Pubitemid 36687067)
14. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP,. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311-318. (Pubitemid 34754077)
15. Nankivell BJ, Fenton-Lee CA, Kuypers DR, et al,. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71: 515-523. (Pubitemid 32207202)
16. Gaston RS,. Chronic calcineurin inhibitor nephrotoxicity: Reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009; 4: 2029-2034.
17. Gaston RS, Cecka JM, Kasiske BL, et al,. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
18. Yates PJ, Nicholson ML,. The aetiology and pathogenesis of chronic allograft nephropathy. Transpl Immunol 2006; 16: 148-157. (Pubitemid 44809923)
19. Hjelmesaeth J, Hartmann A, Leivestad T, et al,. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588-595. (Pubitemid 43164454)
20. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
21. Goldfarb-Rumyantzev AS, Smith L, Shihab FS, et al,. Role of maintenance immunosuppressive regimen in kidney transplant outcome. Clin J Am Soc Nephrol 2006; 1: 563-574.
22. Kaplan B, Schold JD, Meier-Kriesche HU,. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 2003; 14: 2980-2984. (Pubitemid 37305662)
23. Opelz G, Dohler B,. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009; 87: 795-802.
24. Vincenti F, Friman S, Scheuermann E, et al,. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506-1514. (Pubitemid 46776239)